Compulsory licensing moves from legal theory to pandemic-era access strategy
The COVID-19 pandemic turned compulsory licensing from a niche intellectual property doctrine into a live public health instrument. In the analysis published in Georgian Medical News, the central question is not whether patent rights matter, but how far they can be constrained when access to medicines becomes part of the right to health.
The paper treats the issue through a legal and policy lens rather than a clinical trial framework, yet the bedside relevance is unmistakable. When a health system cannot secure enough medicines, patients pay the difference directly, delay treatment, or go without therapy altogether. In Ukraine, 88.2% of medicines were purchased at patients’ own expense, a figure that places heavy pressure on households and leaves the state with limited leverage when demand rises sharply during a pandemic.
Proportionality sits at the center of the legal argument
The analysis builds around one principle: compulsory licensing must be used only in line with proportionality. Patent rights are protected rights, but they are not absolute in the face of a genuine public health threat. Restrictions have to fit the legal framework, match the scale of the emergency, and remain tied to the social purpose they are meant to serve.
That framework matters because pandemic response is often defined by speed. A slow licensing process can leave a country reliant on expensive imports, limited suppliers, or negotiated access that arrives too late for patients who need treatment now. In that setting, legal formality can become a clinical obstacle. The article argues that compulsory licensing is meant to prevent exactly that kind of bottleneck when the market fails to deliver medicines at a population level.
A licensing mechanism that takes months to activate during an outbreak has already lost much of its value.
The paper also stresses that the interests of rights-holders, including medicines manufacturers, cannot simply be dismissed. Their investments, patent protections, and market exclusivity remain part of the legal equation. Yet the same rights are vulnerable to abuse when patent control is used to block access, limit competition, or keep medicines beyond the reach of patients and health systems. The article positions compulsory licensing as a corrective, not as a routine substitute for innovation incentives.
Access to treatment as a legal expression of the right to health
At the center of the analysis is a straightforward public health premise: access to medicines and treatment is a prerequisite for realizing the right to health. Without affordable access, a constitutional or statutory right exists mostly on paper. The paper treats that gap as a matter of social interest, especially during a pandemic when untreated infection, interrupted therapy, and delayed access can ripple across households and communities.
This is where the legal debate becomes clinically consequential. Antiviral agents, supportive therapies, and other essential medicines do not function as abstract commodities once a wave of infections begins. They become tools for reducing suffering, stabilizing severe illness, and preserving health-system capacity. If access is constrained by price or supply, the public health response weakens long before legal disputes are settled.
The paper’s treatment of patent abuse is particularly direct. Rights-holders hold valid legal protections, but those protections may be manipulated in ways that prevent timely access. Compulsory licensing is presented as a lawful response to that imbalance, especially when the social cost of inaction falls on patients who are least able to absorb it.
Ukraine’s legislative gap during epidemic pressure
The article moves beyond theory and into legislative reform, focusing on Ukraine’s current framework. The authors propose expanding the scope of compulsory licensing beyond the medicines themselves to include industrial designs and trade secrets, including know-how. That recommendation reflects a practical concern: access problems are not always confined to a final product patent. Manufacturing constraints, proprietary process knowledge, and related intellectual property can all delay domestic production or local sourcing.
A second proposal is more operational. The procedure for issuing compulsory licenses should be accelerated by government decision during pandemic or epidemic conditions. In plain terms, emergency conditions should trigger a faster administrative pathway rather than forcing the state to wait for a process built for ordinary times. In a public health crisis, delay can turn legal discretion into preventable harm.
The argument is not that governments should bypass rights-holder protections casually. It is that emergency law has to move at a pace compatible with health threat dynamics. When infection curves rise, procurement windows narrow, and hospitals face pressure, the law should not behave as if time were abundant.
What compulsory licensing can and cannot solve
The paper evaluates compulsory licensing as a tool against abuse of patent rights, but it does not treat the mechanism as a cure-all. Its usefulness depends on how clearly the law defines the trigger, how quickly authorities can act, and whether the state has the regulatory capacity to implement the license in practice. A legal authorization without manufacturing capacity, procurement planning, or distribution channels will not improve access by itself.
The analysis also points to a broader global pattern. Compulsory licensing has been used in various contemporary settings, and its relevance tends to increase when medicine access becomes politically and economically strained. During COVID-19, that relevance sharpened because the stakes included both immediate treatment needs and system-wide resilience.
In that sense, the paper reads as a policy argument for preparedness. Countries that anticipate shortages, supply shocks, or pricing disputes can use compulsory licensing as one component of an emergency medicines strategy. The mechanism only works, however, if the legal framework is specific enough to activate quickly and broad enough to cover the forms of intellectual property that can stall access.
Legal reform would need speed, scope, and clearer emergency triggers
The study’s most concrete contribution is its push for legislative refinement in Ukraine. By expanding the categories of protected objects covered by compulsory licensing and shortening the time needed to issue a license during epidemic or pandemic conditions, the system would be better equipped to respond when medicine access is under strain.
That reform agenda rests on a simple public health premise: patents should not become a barrier to treatment when a population is facing a serious threat. At the same time, rights-holder interests remain part of the equation, and any intervention has to stay proportional, legally grounded, and tied to a real health need.
The article leaves one practical question hanging over every emergency framework: whether the existing administrative machinery can actually move fast enough when the next outbreak arrives.